Cannabinoid molecules have untapped potential as a therapeutic platform that is seemingly unprecedented – in both the range of system targets and clinical indications that are addressed, while having an incredible safety/toxicity profile.
Anchored by Charter Research Institute Partners.
An ecosystem of scientists, disease experts, business leaders, investors, and philanthropists gathered to advance the therapeutic potential of cannabinoids.
As alternatives to traditional therapies, millions of consumers believe in the potential – self-dosing with “over-the-counter” cannabis-based products.
However, these products have unregulated, highly variable formulations and no scientifically validated efficacy data.
Ki is focused on REAL SCIENCE, bringing evidence-based, peer reviewed, clinical data-driven effort to a set of molecules that have enormous potential to treat a broad range of serious health conditions.
Access to capital for cannabinoid research & preclinical development has been limited by the Schedule 1 drug status of cannabis.
The risk of research groups losing government grants by working with cannabis has effectively blocked REAL BIOPHARMA EFFORT.
The Ki platform changes this dynamic – providing investor access and transformative capital to an emerging drug discovery platform.
An ecosystem of scientists, disease experts, business leaders, investors, and philanthropists gathered to advance the therapeutic potential of cannabinoids.
The cannabinoid molecules have untapped potential as a therapeutic platform that is seemingly unprecedented in both the range of system targets and clinical indications that are addressed – while having an incredible safety/toxicity profile.
An ecosystem of scientists, disease experts, business leaders, investors, and philanthropists gathered to advance the therapeutic potential of cannabinoids. Ki Collective is focused on bringing REAL SCIENCE – meaning evidence-based, peer reviewed, clinical data-driven effort – to a set of molecules that have enormous potential to treat a broad range of serious health conditions.
Anchored by Charter Research Institute Partners.
An ecosystem of scientists, disease experts, business leaders, investors, and philanthropists gathered to advance the therapeutic potential of cannabinoids
As alternatives to traditional therapies, millions of consumers believe in the potential – self-dosing with “over-the-counter” cannabis-based products.
However, these products have unregulated, highly variable formulations and no scientifically validated efficacy data.
Ki is focused on REAL SCIENCE, bringing evidence-based, peer reviewed, clinical data-driven effort to a set of molecules that have enormous potential to treat a broad range of serious health conditions.
Access to capital for cannabinoid research & preclinical development has been limited by the Schedule 1 drug status of cannabis.
The risk of research groups losing government grants by working with cannabis has effectively blocked REAL BIOPHARMA EFFORT.
Theplatform changes this dynamic – providing investor access and transformative capital to an emerging area drug discovery platform opportunity.
Anchored by Charter Research Institute Partners.
An ecosystem of scientists, disease experts, business leaders, investors, and philanthropists gathered to advance the therapeutic potential of cannabinoids.
As alternatives to traditional therapies, millions of consumers believe in the potential – self-dosing with “over-the-counter” cannabis-based products.
However, these products have unregulated, highly variable formulations and no scientifically validated efficacy data.
Ki is focused on REAL SCIENCE, bringing evidence-based, peer reviewed, clinical data-driven effort to a set of molecules that have enormous potential to treat a broad range of serious health conditions.
Access to capital for cannabinoid research & preclinical development has been limited by the Schedule 1 drug status of cannabis.
The risk of research groups losing government grants by working with cannabis has effectively blocked REAL biopharma effort.
Theplatform changes this dynamic – providing investor access and transformative capital to an emerging area drug discovery platform opportunity.
Ki Translation harnesses the creative freedom of academia, research institutes & independent scientists/entrepreneurs.
We curate a deep research database of leading-edge cannabinoid science deserving of R&D investment attention.
From this pipeline, we invest in the people and ideas having the POTENTIAL to TRANSLATE into clinically validated, life-changing commercial therapies. Ki focuses on discovering what we call “Platform IP”.
Cannabinoids are highly unique molecules - but are challenging in the context of drug development. They are notoriously insoluble compounds, having a high first pass metabolism (very short half-life), with very limited bioavailability, and virtually no standard formulations yet identified. We focus on platform technology that solves for these challenges.
Translation execution typically begins with seed or Series A investment via a special purpose vehicle (SPV) managed by Ki Partners. An SPV is formed for each investment opportunity, with capital raised from an investor network that includes other life sciences investors and strategic partners.
The role of Kᵢ Partners within the Collective is to harness the creative freedom of academia, research institutes & independent scientists/entrepreneurs.Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum
Ki Foundation is a 501(c)3 nonprofit organization established to contribute a portion of Ki Partners' profits to the research of rare diseases where no effective therapies exist.
There are 7000+ rare/orphan diseases per the NIH database. Over 2000 are clinical indications described by some neurological or endocannabinoid system “defect”. Many are potential cannabinoid clinical targets.
Today, rare disease research funding lives in “silos”. We partner with rare disease organizations & patient advocacy groups – connecting these fragmented silos to our horizontal cannabinoid platform.
Together, we can more efficiently fund research and advocate for expanded institutional incentives that close the RESEARCH to TRIAL to TREATMENT timeline and funding gap for rare diseases.
